Image_1_Role of Phosphatidylinositol 3-Kinase (PI3K), Mitogen-Activated Protein Kinase (MAPK), and Protein Kinase C (PKC) in Calcium Signaling Pathways Linked to the α1-Adrenoceptor in Resistance Arteries.JPEG
Insulin resistance plays a key role in the pathogenesis of type 2 diabetes and is also related to other health problems like obesity, hypertension, and metabolic syndrome. Imbalance between insulin vascular actions via the phosphatidylinositol 3-Kinase (PI3K) and the mitogen activated protein kinase (MAPK) signaling pathways during insulin resistant states results in impaired endothelial PI3K/eNOS- and augmented MAPK/endothelin 1 pathways leading to endothelial dysfunction and abnormal vasoconstriction. The role of PI3K, MAPK, and protein kinase C (PKC) in Ca2+ handling of resistance arteries involved in blood pressure regulation is poorly understood. Therefore, we assessed here whether PI3K, MAPK, and PKC play a role in the Ca2+ signaling pathways linked to adrenergic vasoconstriction in resistance arteries. Simultaneous measurements of intracellular calcium concentration ([Ca2+]i) in vascular smooth muscle (VSM) and tension were performed in endothelium-denuded branches of mesenteric arteries from Wistar rats mounted in a microvascular myographs. Responses to CaCl2 were assessed in arteries activated with phenylephrine (PE) and kept in Ca2+-free solution, in the absence and presence of the selective antagonist of L-type Ca2+ channels nifedipine, cyclopiazonic acid (CPA) to block sarcoplasmic reticulum (SR) intracellular Ca2+ release or specific inhibitors of PI3K, ERK-MAPK, or PKC. Activation of α1-adrenoceptors with PE stimulated both intracellular Ca2+ mobilization and Ca2+ entry along with contraction in resistance arteries. Both [Ca2+]i and contractile responses were inhibited by nifedipine while CPA abolished intracellular Ca2+ mobilization and modestly reduced Ca2+ entry suggesting that α1-adrenergic vasoconstriction is largely dependent Ca2+ influx through L-type Ca2+ channel and to a lesser extent through store-operated Ca2+ channels. Inhibition of ERK-MAPK did not alter intracellular Ca2+ mobilization but largely reduced L-type Ca2+ entry elicited by PE without altering vasoconstriction. The PI3K blocker LY-294002 moderately reduced intracellular Ca2+ release, Ca2+ entry and contraction induced by the α1-adrenoceptor agonist, while PKC inhibition decreased PE-elicited Ca2+ entry and to a lesser extent contraction without affecting intracellular Ca2+ mobilization. Under conditions of ryanodine receptor (RyR) blockade to inhibit Ca2+-induced Ca2+-release (CICR), inhibitors of PI3K, ERK-MAPK, or PKC significantly reduced [Ca2+]i increases but not contraction elicited by high K+ depolarization suggesting an activation of L-type Ca2+ entry in VSM independent of RyR. In summary, our results demonstrate that PI3K, ERK-MAPK, and PKC regulate Ca2+ handling coupled to the α1-adrenoceptor in VSM of resistance arteries and related to both contractile and non-contractile functions. These kinases represent potential pharmacological targets in pathologies associated to vascular dysfunction and abnormal Ca2+ handling such as obesity, hypertension and diabetes mellitus, in which these signaling pathways are profoundly impaired.
History
References
- https://doi.org//10.1016/j.yjmcc.2017.01.015
- https://doi.org//10.1124/jpet.105.100040
- https://doi.org//10.1111/j.1469-7793.1998.577bk.x
- https://doi.org//10.1161/hy0202.103129
- https://doi.org//10.1093/cvr/cvs166
- https://doi.org//10.1152/ajpheart.01261.2006
- https://doi.org//10.1111/j.1476-5381.2010.00825.x
- https://doi.org//10.1093/ajh/hpw201
- https://doi.org//10.2337/diacare.28.7.1769
- https://doi.org//10.1016/j.jacc.2009.10.060
- https://doi.org//10.1161/CIRCRESAHA.110.217117
- https://doi.org//10.1161/CIRCRESAHA.117.310183
- https://doi.org//10.1113/jphysiol.2003.047050
- https://doi.org//10.1152/ajpcell.00381.2011
- https://doi.org//10.1074/jbc.M311604200
- https://doi.org//10.1161/CIRCULATIONAHA.105.563213
- https://doi.org//10.1113/jphysiol.2012.241315
- https://doi.org//10.1111/febs.12414
- https://doi.org//10.1161/01.RES.0000138017.76125.8b
- https://doi.org//10.1016/j.bcp.2018.02.012
- https://doi.org//10.1161/CIRCULATIONAHA.109.873380
- https://doi.org//10.2337/db06-1629
- https://doi.org//10.1161/hh2001.097864
- https://doi.org//10.1152/ajpheart.2000.279.3.H1228
- https://doi.org//10.1159/000341230
- https://doi.org//10.1085/jgp.201711878
- https://doi.org//10.1161/01.RES.41.1.19
- https://doi.org//10.1152/ajpregu.00245.2005
- https://doi.org//10.1161/hh1201.092035
- https://doi.org//10.3349/ymj.2011.52.3.420
- https://doi.org//10.2337/diabetes.54.8.2415
- https://doi.org//10.1111/j.1476-5381.2010.00955.x
- https://doi.org//10.1167/iovs.12-9542
- https://doi.org//10.1111/j.1476-5381.1991.tb09850.x
- https://doi.org//10.1074/jbc.M102582200
- https://doi.org//10.1016/j.bcp.2018.03.020
- https://doi.org//10.1111/bph.13322
- https://doi.org//10.1093/cvr/cvq063
- https://doi.org//10.1152/physrev.00023.2003
- https://doi.org//10.1161/01.RES.0000126405.38858.BC
- https://doi.org//10.1161/01.RES.84.5.505
- https://doi.org//10.1016/j.febslet.2010.12.022
- https://doi.org//10.1016/S0008-6363(99)00106-6
- https://doi.org//10.1038/nn1300
- https://doi.org//10.1152/ajpheart.01204.2010
- https://doi.org//10.1152/ajpheart.01034.2006
- https://doi.org//10.1152/ajpheart.01221.2007
- https://doi.org//10.1042/BJ20051471
- https://doi.org//10.1021/bi900322a